SEC Form 4 · accession 0000874015-17-000049
IONIS PHARMACEUTICALS INC · IONS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brett P Monia
Officer — SVP, Antisense Drug Discovery
Period of report
Jul 1, 2017
Accepted (ET)
Jul 3, 2017 · 5:38 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000874015
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 1, 2017 | J | 163 | $40.6555 | A | 11,935 | D | |
| Common StockF2 | Jul 3, 2017 | S | 309 | $51.35 | D | 11,626 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reporting 163 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2017. These 163 shares may not be sold until January 2, 2018.
- F2The sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 7/1/2014.